Renal Cell Carcinoma and the General Medical Oncologist: Where We Are and Where We’re HeadedFirst-line systemic treatment: Sunitinib vs pazopanib
2:01 minutes.
TRANSCRIPTION:
DR STADLER: We’ve had a tendency over the last year or two to lead with pazopanib. I’ve been reasonably impressed with the data that the 2 drugs are relatively equivalent in regards to outcome and disease outcome and yet some better tolerability with pazopanib. I think that the one caveat is the issue of liver toxicity is a little bit higher with pazopanib, and one has to be a little bit more careful with that. DR LOVE: Dr Motzer, very interested in your answer to this question. DR MOTZER: I always exclusively gave sunitinib and treated lots of patients, hundreds of patients with sunitinib. I first became acquainted with pazopanib as a participant in the COMPARZ trial. And my impression was that while about 1 out of 10 patients develop elevated liver function tests and have to stop pazopanib, the other 9 out of 10 feel better over the course of their treatment with the drug, with less fatigue and an almost absence of hand-foot syndrome. So then when the COMPARZ data became available to me, it was somewhat difficult for me to that transition because I was so used to giving sunitinib. But I switched over my practice and now I give pazopanib. And in my own experience, it confirms the COMPARZ data, where I think that in general most patients experience a better quality of life with the pazopanib. The 2 side effects that my patients found particularly troublesome were fatigue and also particularly hand-foot syndrome, which interfered with a lot of their activity. And that seems to be much less common with pazopanib. |